The global immunoglobulin market is projected to grow from USD 15.35 billion in 2025 to USD 28.70 billion by 2034, expanding at a CAGR of 7.20%. This growth is driven by the rising prevalence of immunodeficiency and autoimmune diseases, an aging population, and broader therapeutic applications. Increasing adoption of subcutaneous delivery methods and continued R&D advancements further support market expansion.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Immunoglobulin Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Immunoglobulin Market, by Application
8.1.1 Hypogammaglobulinemia
8.1.1.1. Market Revenue and Forecast
8.1.2. Chronic Inflammatory Demyelinating Polyneuropathy
8.1.2.1. Market Revenue and Forecast
8.1.3. Immunodeficiency Disease
8.1.3.1. Market Revenue and Forecast
8.1.4. Myasthenia Gravis
8.1.4.1. Market Revenue and Forecast
8.1.5. Multifocal Motor Neuropathy
8.1.5.1. Market Revenue and Forecast
8.1.6. Idiopathic Thrombocytopenic Purpura
8.1.6.1. Market Revenue and Forecast
8.1.7. Inflammatory Myopathies
8.1.7.1. Market Revenue and Forecast
8.1.8. Specific Antibody Deficiency
8.1.8.1. Market Revenue and Forecast
8.1.9. Guillain Barre Syndrome
8.1.9.1. Market Revenue and Forecast
8.1.10. Others
8.1.10.1. Market Revenue and Forecast
9.1. Immunoglobulin Market, by Product
9.1.1. IgA
9.1.1.1. Market Revenue and Forecast
9.1.2. IgG
9.1.2.1. Market Revenue and Forecast
9.1.3. IgM
9.1.3.1. Market Revenue and Forecast
9.1.4. IgE
9.1.4.1. Market Revenue and Forecast
9.1.5. IgD
9.1.5.1. Market Revenue and Forecast
10.1. Immunoglobulin Market, by Mode of Delivery
10.1.1. Intravenous
10.1.1.1. Market Revenue and Forecast
10.1.2. Subcutaneous
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application
11.1.2. Market Revenue and Forecast, by Product
11.1.3. Market Revenue and Forecast, by Mode of Delivery
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application
11.1.4.2. Market Revenue and Forecast, by Product
11.1.4.3. Market Revenue and Forecast, by Mode of Delivery
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application
11.1.5.2. Market Revenue and Forecast, by Product
11.1.5.3. Market Revenue and Forecast, by Mode of Delivery
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application
11.2.2. Market Revenue and Forecast, by Product
11.2.3. Market Revenue and Forecast, by Mode of Delivery
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application
11.2.4.2. Market Revenue and Forecast, by Product
11.2.4.3. Market Revenue and Forecast, by Mode of Delivery
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application
11.2.5.2. Market Revenue and Forecast, by Product
11.2.5.3. Market Revenue and Forecast, by Mode of Delivery
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application
11.2.6.2. Market Revenue and Forecast, by Product
11.2.6.3. Market Revenue and Forecast, by Mode of Delivery
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application
11.2.7.2. Market Revenue and Forecast, by Product
11.2.7.3. Market Revenue and Forecast, by Mode of Delivery
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application
11.3.2. Market Revenue and Forecast, by Product
11.3.3. Market Revenue and Forecast, by Mode of Delivery
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application
11.3.4.2. Market Revenue and Forecast, by Product
11.3.4.3. Market Revenue and Forecast, by Mode of Delivery
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application
11.3.5.2. Market Revenue and Forecast, by Product
11.3.5.3. Market Revenue and Forecast, by Mode of Delivery
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application
11.3.6.2. Market Revenue and Forecast, by Product
11.3.6.3. Market Revenue and Forecast, by Mode of Delivery
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application
11.3.7.2. Market Revenue and Forecast, by Product
11.3.7.3. Market Revenue and Forecast, by Mode of Delivery
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application
11.4.2. Market Revenue and Forecast, by Product
11.4.3. Market Revenue and Forecast, by Mode of Delivery
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application
11.4.4.2. Market Revenue and Forecast, by Product
11.4.4.3. Market Revenue and Forecast, by Mode of Delivery
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application
11.4.5.2. Market Revenue and Forecast, by Product
11.4.5.3. Market Revenue and Forecast, by Mode of Delivery
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application
11.4.6.2. Market Revenue and Forecast, by Product
11.4.6.3. Market Revenue and Forecast, by Mode of Delivery
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application
11.4.7.2. Market Revenue and Forecast, by Product
11.4.7.3. Market Revenue and Forecast, by Mode of Delivery
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application
11.5.2. Market Revenue and Forecast, by Product
11.5.3. Market Revenue and Forecast, by Mode of Delivery
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application
11.5.4.2. Market Revenue and Forecast, by Product
11.5.4.3. Market Revenue and Forecast, by Mode of Delivery
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application
11.5.5.2. Market Revenue and Forecast, by Product
11.5.5.3. Market Revenue and Forecast, by Mode of Delivery
12.1. Grifols, S.A.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Shire
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. CSL Behring
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Kedrion S.p.A.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Octapharma
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Baxter International Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Biotest AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bio Products Laboratory Ltd. (BPL)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. China Biologic Products Holdings, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. LFB SA
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description